LBT Stock Overview
LBT Innovations Limited engages in the research, development, and commercialization of technologies for the healthcare and laboratory supply markets in Australia, the United States, Sweden, the United Kingdom, and Germany.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
LBT Innovations Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.019 |
| 52 Week High | AU$0.042 |
| 52 Week Low | AU$0.004 |
| Beta | 1.36 |
| 1 Month Change | -26.92% |
| 3 Month Change | 26.67% |
| 1 Year Change | -50.00% |
| 3 Year Change | -78.41% |
| 5 Year Change | -75.00% |
| Change since IPO | -90.26% |
Recent News & Updates
Recent updates
Should Shareholders Reconsider LBT Innovations Limited's (ASX:LBT) CEO Compensation Package?
Nov 23
Is LBT Innovations (ASX:LBT) Using Debt Sensibly?
Sep 09Is LBT Innovations (ASX:LBT) Using Debt In A Risky Way?
Sep 15Is LBT Innovations (ASX:LBT) Using Too Much Debt?
May 04How Much Is LBT Innovations Limited (ASX:LBT) Paying Its CEO?
Jan 04Shareholder Returns
| LBT | AU Medical Equipment | AU Market | |
|---|---|---|---|
| 7D | -5.0% | 0.5% | 0.9% |
| 1Y | -50.0% | 13.1% | 5.7% |
Return vs Industry: LBT underperformed the Australian Medical Equipment industry which returned 13.8% over the past year.
Return vs Market: LBT underperformed the Australian Market which returned 5.6% over the past year.
Price Volatility
| LBT volatility | |
|---|---|
| LBT Average Weekly Movement | 33.3% |
| Medical Equipment Industry Average Movement | 10.2% |
| Market Average Movement | 8.9% |
| 10% most volatile stocks in AU Market | 17.5% |
| 10% least volatile stocks in AU Market | 3.5% |
Stable Share Price: LBT's share price has been volatile over the past 3 months.
Volatility Over Time: LBT's weekly volatility (33%) has been stable over the past year, but is still higher than 75% of Australian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 19 | Brent Barnes | www.lbtinnovations.com |
LBT Innovations Limited engages in the research, development, and commercialization of technologies for the healthcare and laboratory supply markets in Australia, the United States, Sweden, the United Kingdom, and Germany. Its products portfolio comprises Automated Plate Assessment System (APAS) Independence, a platform technology that automates culture-plate screening and interpretation; APAS Analysis Modules, an intelligent image analysis software that enables the screening of microbiology culture plates; APAS antimicrobial resistance (AMR) Analysis Module that reads and interprets antimicrobial susceptibility tests (ASTs) for the detection of AMR; and APAS PharmaQC, which provides automated imaging, analysis, and interpretation of microbiology culture plates used in environmental monitoring. The company’s products pipeline also includes Automated Gram Strain Assessment for the automated interpretation of gram stain image analysis; Biofilm, a device for detecting the biofilms in the presence of mammalian tissues; and WoundVue, a technology that uses artificial intelligence to assist clinicians in the assessment and care of chronic wounds.
LBT Innovations Limited Fundamentals Summary
| LBT fundamental statistics | |
|---|---|
| Market cap | AU$25.45m |
| Earnings (TTM) | -AU$21.37m |
| Revenue (TTM) | AU$1.98m |
12.8x
P/S Ratio-1.2x
P/E RatioIs LBT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LBT income statement (TTM) | |
|---|---|
| Revenue | AU$1.98m |
| Cost of Revenue | AU$105.00k |
| Gross Profit | AU$1.88m |
| Other Expenses | AU$23.25m |
| Earnings | -AU$21.37m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.016 |
| Gross Margin | 94.71% |
| Net Profit Margin | -1,077.37% |
| Debt/Equity Ratio | 68.3% |
How did LBT perform over the long term?
See historical performance and comparison